Tumor Electric Fields Treatment System for Glioblastoma

Inclusion Criteria:

* Patients with pathological diagnosis of glioblastoma at first surgery (WHO Grade IV, supratentorial location);
* Age between 18 and 65 years, male or female;
* Previously completed radiotherapy and at least two cycles of chemotherapy;
* With imaging or pathological evidence of tumor recurrence;
* Karnofsky performance score (KPS) score ≥ 70 before intervention;
* With a life expectancy more than 3 months;
* Adopted effective contraceptive measures at child-bearing age;
* Provided written informed consent.

Exclusion Criteria:

* Patients unwilling to use the equipment ≥ 18h per day;
* With poor compliance or live too far from the research center, who cannot keep regular follow-up or adjust the electrode position of the treatment equipment, and who refuse to receive follow-up to terminal survival;
* With poor healing of scalp wound, poor scalp condition, large skull defect or other cases where electrodes are not suitable for wearing;
* Within 3 months from radiotherapy;
* Within 4 weeks from the last cycle of chemotherapy;
* Within 4 weeks from surgery for recurrence;
* Participated in other clinical trials.
* Pregnant;
* Epilepsy symptoms not effectively controlled;
* Blood and biochemical indicators in the following range: A. Liver function impairment: AST or ALT \> 3 times the upper limit of normal; B. Total bilirubin\> upper limit of normal value; C. Renal impairment: serum creatinine\>1.7mg /dL (\>150 mol/L); D. Coagulopathy: PT or APTT \>1.5 times normal; E. Platelets counts \< 100x10\^9/L; F. Absolute neutrophils count \< 1x10\^9/L; G. Hemoglobin \< 100g/L;
* With severe infectious diseases, such as acute severe infection and HIV positive;
* Other conditions, such as an implanted cardiac pacemaker or deep brain stimulator, severe intracranial edema, increased intracranial pressure resulting in midline shift\>5mm, clinically significant papilledema, or reduced level of consciousness, allergy to conductive coupling agent, gel, and other serious life-threatening diseases.
* Other circumstances considered inappropriate to participate in the research by the investigator.